Program
pucotenlimab
Also written as “HX008”, “MRG003+HX008” and “MRG003 + Pucotenlimab”.
Its studies are mostly in Melanoma · Nasopharyngeal Carcinoma · Colorectal Neoplasms · Gastrointestinal Neoplasms · Triple Negative Breast Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Taizhou Hanzhong biomedical | 102 open or running | phase 3since Jul 22, 2020 | Jul 22, 2020 | none ahead |
| Binhui Biopharmaceutical | 22 open or running | phase 2since Feb 28, 2019 | Feb 28, 2019 | none ahead |
| Lepu Biopharma | 22 open or running | phase 3since May 8, 2025 | Jan 6, 2023 | Aug 2027phase 2 · NCT05688605 |
| Shanghai Miracogen | 10 open or running | phase 2since Apr 15, 2022 | Apr 15, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 28, 2019First study: phase 2 study in Gastrointestinal NeoplasmsNew to Binhui BiopharmaceuticalBinhui Biopharmaceutical · NCT03866525 · 300 planned · China
- Jul 22, 2020Taizhou Hanzhong biomedical's first study: phase 3 study in Stomach NeoplasmsNew to Taizhou Hanzhong biomedicalTaizhou Hanzhong biomedical · NCT04486651 · 560 enrolled · China
- Aug 31, 2020Phase 2 study in MelanomaBinhui Biopharmaceutical · NCT04616443 · 60 planned · China
- Sep 29, 2020Phase 2 study in Thyroid Carcinoma, AnaplasticTaizhou Hanzhong biomedical · NCT04574817 · 66 enrolled · China
- Jan 31, 2021Phase 2 study in Urinary Bladder NeoplasmsTaizhou Hanzhong biomedical · NCT04738630 · 110 enrolled · China
- Feb 2, 20213 phase 2 studiesTaizhou Hanzhong biomedical · NCT04741165, NCT04749485, NCT04750382
- Feb 3, 2021Phase 3 study in Nonsquamous Non-small Cell Lung CancerTaizhou Hanzhong biomedical · NCT04750083 · 700 enrolled · China
- Mar 28, 2021Phase 1 study in Advanced Solid TumorTaizhou Hanzhong biomedical · NCT04825392 · 30 enrolled · China
- Apr 15, 2022Shanghai Miracogen's first study: phase 2 study in Advanced Malignant Solid TumorsNew to Shanghai MiracogenShanghai Miracogen · NCT05338957 · 30 enrolled · China
- Nov 26, 20222 phase 3 studiesTaizhou Hanzhong biomedical · NCT05652894, NCT05647954
- Jan 6, 2023Lepu Biopharma's first study: phase 2 study in Advanced Solid TumorsNew to Lepu BiopharmaLepu Biopharma · NCT05688605 · 18 planned · China
- May 8, 2025Phase 3 study in RecurrenceLepu Biopharma · NCT06976190 · 446 planned · China
Ahead
- Aug 2027Primary completion: phase 2 study in Advanced Solid TumorsLepu Biopharma · NCT05688605
- May 2029Primary completion: phase 3 study in RecurrenceLepu Biopharma · NCT06976190
TargetBeta
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
| sasanlimab | Pfizer | phase 3 | 4 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06976190Recurrence · China | 3 | Recruiting | Lepu Biopharma | May 2029 | 446 |
| NCT05688605Advanced Solid Tumors · China | 2 | Recruiting | Lepu Biopharma | Aug 2027 | 18 |
| NCT05647954Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms · China | 3 | Not yet recruiting | Taizhou Hanzhong biomedical | Dec 30, 2024 | 350 |
| NCT05652894Colorectal Neoplasms · China | 3 | Active, not recruiting | Taizhou Hanzhong biomedical | Jun 30, 2026 | 190 |
| NCT05338957Advanced Malignant Solid Tumors · China | 2 | UNKNOWN | Shanghai Miracogen | Jun 2024 | 30 |
| NCT04825392Advanced Solid Tumor · China | 1 | UNKNOWN | Taizhou Hanzhong biomedical | May 30, 2021 | 30 |
| NCT04750382Triple Negative Breast Neoplasms · China | 2 | UNKNOWN | Taizhou Hanzhong biomedical | Dec 1, 2020 | 31 |
| NCT04749485Melanoma · China | 2 | UNKNOWN | Taizhou Hanzhong biomedical | Aug 19, 2020 | 119 |
| NCT04750083Nonsquamous Non-small Cell Lung Cancer · China | 3 | UNKNOWN | Taizhou Hanzhong biomedical | Sep 25, 2022 | 700 |
| NCT04741165Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Taizhou Hanzhong biomedical | Apr 30, 2022 | 72 |
| NCT04738630Urinary Bladder Neoplasms · China | 2 | UNKNOWN | Taizhou Hanzhong biomedical | Dec 1, 2022 | 110 |
| NCT04574817Thyroid Carcinoma, Anaplastic · China | 2 | UNKNOWN | Taizhou Hanzhong biomedical | May 30, 2022 | 66 |
| NCT04616443Melanoma · China | 2 | Recruiting | Binhui Biopharmaceutical | Nov 30, 2025 | 60 |
| NCT04486651Stomach Neoplasms · China | 3 | UNKNOWN | Taizhou Hanzhong biomedical | Aug 10, 2023 | 560 |
| NCT03866525Gastrointestinal Neoplasms · China | 2 | Recruiting | Binhui Biopharmaceutical | Aug 30, 2025 | 300 |
How it is read
Names in the registry
- “HX008”, 7 entries
- “MRG003+HX008”, 1 entry
- “MRG003 + Pucotenlimab”, 1 entry
- “HX008(Pucotenlimab)”, 1 entry
- “HX008 injection”, 1 entry
Codes read as this program: HX008.
Conditions, from the studies’ own filings
- Melanoma, 3 studies
- Nasopharyngeal Carcinoma, 1 study
- Colorectal Neoplasms, 1 study
- Gastrointestinal Neoplasms, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.